232 related articles for article (PubMed ID: 11380495)
1. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid.
Papotti M; Kumar U; Volante M; Pecchioni C; Patel YC
Clin Endocrinol (Oxf); 2001 May; 54(5):641-9. PubMed ID: 11380495
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study.
Bertherat J; Tenenbaum F; Perlemoine K; Videau C; Alberini JL; Richard B; Dousset B; Bertagna X; Epelbaum J
J Clin Endocrinol Metab; 2003 Nov; 88(11):5353-60. PubMed ID: 14602773
[TBL] [Abstract][Full Text] [Related]
3. Comparative evaluation of somatostatin and CXCR4 receptor expression in different types of thyroid carcinoma using well-characterised monoclonal antibodies.
Czajkowski M; Kaemmerer D; Sänger J; Sauter G; Wirtz RM; Schulz S; Lupp A
BMC Cancer; 2022 Jul; 22(1):740. PubMed ID: 35799158
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin receptor expression in non-medullary thyroid carcinomas.
Pazaitou-Panayiotou K; Tiensuu Janson E; Koletsa T; Kotoula V; Stridsberg M; Karkavelas G; Karayannopoulou G
Hormones (Athens); 2012; 11(3):290-6. PubMed ID: 22908061
[TBL] [Abstract][Full Text] [Related]
5. Expression and localisation of somatostatin receptor subtypes sst1-sst5 in areas of the rat medulla oblongata involved in autonomic regulation.
Spary EJ; Maqbool A; Batten TF
J Chem Neuroanat; 2008 Jan; 35(1):49-66. PubMed ID: 17646081
[TBL] [Abstract][Full Text] [Related]
6. Modulation of pituitary somatostatin receptor subtype (sst1-5) messenger ribonucleic acid levels by changes in the growth hormone axis.
Park S; Kamegai J; Johnson TA; Frohman LA; Kineman RD
Endocrinology; 2000 Oct; 141(10):3556-63. PubMed ID: 11014208
[TBL] [Abstract][Full Text] [Related]
7. Binding properties of somatostatin receptor subtypes.
Bruns C; Raulf F; Hoyer D; Schloos J; Lübbert H; Weckbecker G
Metabolism; 1996 Aug; 45(8 Suppl 1):17-20. PubMed ID: 8769372
[TBL] [Abstract][Full Text] [Related]
8. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
[TBL] [Abstract][Full Text] [Related]
9. Characterisation of [125I]-Tyr0DTrp8-somatostatin binding in sst1- to sst4- and SRIF-gene-invalidated mouse brain.
Videau C; Hochgeschwender U; Kreienkamp HJ; Brennan MB; Viollet C; Richter D; Epelbaum J
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):562-71. PubMed ID: 12759718
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and somatostatin receptor subtype gene expression in medullary thyroid carcinoma.
Mato E; Matías-Guiu X; Chico A; Webb SM; Cabezas R; Berná L; De Leiva A
J Clin Endocrinol Metab; 1998 Jul; 83(7):2417-20. PubMed ID: 9661621
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical detection of somatostatin receptor subtypes sst1 and sst2A in human somatostatin receptor positive tumors.
Hofland LJ; Liu Q; Van Koetsveld PM; Zuijderwijk J; Van Der Ham F; De Krijger RR; Schonbrunn A; Lamberts SW
J Clin Endocrinol Metab; 1999 Feb; 84(2):775-80. PubMed ID: 10022452
[TBL] [Abstract][Full Text] [Related]
12. Pituitary somatostatin receptor (sst)1-5 expression during rat development: age-dependent expression of sst2.
Reed DK; Korytko AI; Hipkin RW; Wehrenberg WB; Schonbrunn A; Cuttler L
Endocrinology; 1999 Oct; 140(10):4739-44. PubMed ID: 10499533
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.
Reubi JC; Waser B; Schaer JC; Laissue JA
Eur J Nucl Med; 2001 Jul; 28(7):836-46. PubMed ID: 11504080
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor subtype expression in cells of the rat immune system during adjuvant arthritis.
ten Bokum AM; Lichtenauer-Kaligis EG; Melief MJ; van Koetsveld PM; Bruns C; van Hagen PM; Hofland LJ; Lamberts SW; Hazenberg MP
J Endocrinol; 1999 Apr; 161(1):167-75. PubMed ID: 10194540
[TBL] [Abstract][Full Text] [Related]
15. Drug design at peptide receptors: somatostatin receptor ligands.
Hannon JP; Nunn C; Stolz B; Bruns C; Weckbecker G; Lewis I; Troxler T; Hurth K; Hoyer D
J Mol Neurosci; 2002; 18(1-2):15-27. PubMed ID: 11931345
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptors: from basic science to clinical approach--thyroid.
Zatelli MC; degli Uberti EC
Dig Liver Dis; 2004 Feb; 36 Suppl 1():S86-92. PubMed ID: 15077916
[TBL] [Abstract][Full Text] [Related]
17. Expression of somatostatin receptor 2A in medullary thyroid carcinoma is associated with lymph node metastasis.
Herac M; Niederle B; Raderer M; Krebs M; Kaserer K; Koperek O
APMIS; 2016 Oct; 124(10):839-45. PubMed ID: 27539746
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours.
Unger N; Serdiuk I; Sheu SY; Walz MK; Schulz S; Saeger W; Schmid KW; Mann K; Petersenn S
Clin Endocrinol (Oxf); 2008 Jun; 68(6):850-7. PubMed ID: 18031328
[TBL] [Abstract][Full Text] [Related]
19. Expression of somatostatin receptor subtypes in human brain tumors.
Dutour A; Kumar U; Panetta R; Ouafik L; Fina F; Sasi R; Patel YC
Int J Cancer; 1998 May; 76(5):620-7. PubMed ID: 9610716
[TBL] [Abstract][Full Text] [Related]
20. SSTR2A expression in medullary thyroid carcinoma is correlated with longer survival.
de Vries LH; Lodewijk L; Willems SM; Dreijerink KMA; de Keizer B; van Diest PJ; Schepers A; Bonenkamp HJ; van Engen-van Grunsven IACH; Kruijff S; van Hemel BM; Links TP; Nieveen van Dijkum EJM; van Eeden S; Valk GD; Borel Rinkes IHM; Vriens MR
Endocrine; 2018 Dec; 62(3):639-647. PubMed ID: 30128959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
